X

Trial Profile

Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amantadine (Primary)
Indications Movement disorders
Focus Adverse reactions; Proof of concept
Sponsors Adamas Pharmaceuticals

Most Recent Events

01 Feb 2018 According to an Adamas Pharmaceuticals media release, results published online in Multiple Sclerosis Journal.
01 Feb 2018 Results published in the Media Release
17 Feb 2017 Results published in the Adamas Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com